- Home
- VNRX vs NCEL Comparison
VNRX vs NCEL Comparison
Compare VNRX & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNRX | NCEL |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 4 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 20.6M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | VNRX | NCEL |
|---|---|---|
| Price | $2.42 | $3.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.67 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 74.0K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,727,384.00 | N/A |
| Revenue This Year | $355.66 | N/A |
| Revenue Next Year | $849.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.13 | $1.83 |
| 52 Week High | $2.89 | $5.12 |
Technical Indicators
Market Signals| Indicator | VNRX | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 79.62 | 50.53 |
| Support Level | $0.22 | $2.21 |
| Resistance Level | $2.89 | $4.38 |
| Average True Range (ATR) | 0.16 | 0.61 |
| MACD | 0.17 | -0.06 |
| Stochastic Oscillator | 82.83 | 26.95 |
Price Performance
Historical ComparisonAbout VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.